Literature DB >> 28711461

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study.

Alejandro Balsa1, Leticia Lojo-Oliveira2, Mercedes Alperi-López3, María García-Manrique4, Carmen Ordóñez-Cañizares5, Lorena Pérez6, Virginia Ruiz-Esquide7, Alfonso Corrales8, Javier Narváez9, José Rey-Rey10, Carlos Rodríguez-Lozano11, Soledad Ojeda11, Santiago Muñoz-Fernández6, Joan M Nolla9, José García-Torrón12, Fernando Gamero12, Rosario García-Vicuña13, Blanca Hernández-Cruz14, José Campos15, José Rosas16, José Francisco García-Llorente17, Antonio Gómez-Centeno4, Rafael Cáliz18, Raimon Sanmartí7, Alberto Bermúdez19, Lydia Abasolo-Alcázar20, Antonio Fernández-Nebro5, Luis Rodríguez-Rodríguez20, Carlos Marras19, Miguel Ángel González-Gay8, Ihsane Hmamouchi21, Emilio Martín-Mola2.   

Abstract

OBJECTIVES: To describe the prevalence of comorbidities in patients with RA in Spain and discuss their management and implications using data from the Spanish cohort of the multinational study on COMOrbidities in Rheumatoid Arthritis (COMORA).
METHODS: This is a national sub-analysis of the COMORA study. We studied the demographics and disease characteristics of 200 adults patients diagnosed with RA (1987 ACR), and routine practices for screening and preventing the following selected comorbidities: cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and depression.
RESULTS: Patients had a mean age of 58 years and a mean RA duration of 10 years. Mean DAS28 score was 3.3 and approximately 25% of patients were in remission (DAS28 <2.6). Forty-four (22%) patients had ≥1 comorbidity, the most frequent being depression (27%) and obesity (26%). A history of myocardial infarction or stroke was observed in 5% and 1% of patients, respectively, and any solid tumor in 6%. Having a Framingham Risk Score >20% (51%), hypercholesterolemia (46%) or hypertension (41%) and smoking (25%) were the most common CV risk factors. For prostate, colon and skin cancers, only 9%, 10% and 18% of patients, respectively, were optimally monitored. Infections were also inadequately managed, with 7% and 17% of patients vaccinated against influenza and pneumococcal, respectively, as was osteoporosis, with 47% of patients supplemented with vitamin D and 56% with a bone densitometry performed.
CONCLUSIONS: In Spain, the prevalence of comorbidities and CV risk factors in RA patients with established and advanced disease is relatively high, and their management in clinical daily practice remains suboptimal.
Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Artritis reumatoide; Comorbidities; Comorbilidades; Factores de riesgo; Prevalence; Prevalencia; Rheumatoid arthritis; Risk factors

Mesh:

Year:  2017        PMID: 28711461     DOI: 10.1016/j.reuma.2017.06.002

Source DB:  PubMed          Journal:  Reumatol Clin (Engl Ed)        ISSN: 2173-5743


  8 in total

1.  Increased short-term risk of cardiovascular events in inflammatory rheumatic diseases: results from a population-based cohort.

Authors:  Vital Da Silva Domingues; Ana M Rodrigues; Sara S Dias; Luís Delgado; Ebrahim Barkoudah; Jaime Branco; Helena Canhão
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 2.631

2.  Expert recommendations on the psychological needs of patients with rheumatoid arthritis.

Authors:  Leticia Leon; Marta Redondo; Antonio Fernández-Nebro; Susana Gómez; Estíbaliz Loza; María Montoro; Rosario Garcia-Vicuña; María Galindo
Journal:  Rheumatol Int       Date:  2018-05-28       Impact factor: 2.631

Review 3.  Mechanisms of vascular comorbidity in autoimmune diseases.

Authors:  György Nagy; Nóra Németh; Edit I Buzás
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

4.  Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.

Authors:  Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Elisabetta Gerratana; Caterina Palleria; Caterina De Sarro; Ada Vero; Luigi Iannone; Antonia Manti; Emilio Russo; Giovambattista De Sarro; Fabiola Atzeni; Edoardo Spina
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

5.  Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study.

Authors:  Vasyl Yagensky; Michael Schirmer
Journal:  Front Med (Lausanne)       Date:  2022-02-22

6.  An Advanced Clinician Practitioner in Arthritis Care (ACPAC) Maintains a Positive Patient Experience While Increasing Capacity in Rheumatology Community Care.

Authors:  Vandana Ahluwalia; Taucha Inrig; Tiffany Larsen; Rachel Shupak; Tripti Papneja; Arthur Karasik; Carol Kennedy; Katie Lundon
Journal:  J Multidiscip Healthc       Date:  2021-06-03

7.  Trends in hip fracture in patients with rheumatoid arthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999-2015). TREND-AR study.

Authors:  Ramón Mazzucchelli; Elia Pérez Fernandez; Natalia Crespí-Villarías; Javier Quirós-Donate; Alberto García Vadillo; María Espinosa; Marina Peña; Cristina Macía-Villa; Jose Luis Morell-Hita; Cristina Martinez-Prada; Virginia Villaverde; Inmaculada Morado Quiroga; Olalla Guzón-Illescas; Carmen Barbadillo; Manuel Fernández Prada; Hilda Godoy; Angela Herranz Varela; María Galindo Izquierdo; Gil Rodriguez Caravaca
Journal:  RMD Open       Date:  2018-06-04

8.  Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.

Authors:  Gustavo Nogueira Schincariol Vicente; Ivânio Alves Pereira; Gláucio Ricardo Werner de Castro; Licia Maria Henrique da Mota; Ana Paula Carnieletto; Dhara Giovanna Santin de Souza; Fabiana Oenning da Gama; Ana Beatriz Vargas Santos; Cleandro Pires de Albuquerque; Manoel Barros Bértolo; Paulo Louzada Júnior; Rina Dalva Neubarth Giorgi; Sebastião Cezar Radominski; Maria Fernanda Brandão Resende Guimarães; Karina Rossi Bonfiglioli; Maria de Fátima Lobato da Cunha Sauma; Claiton Viegas Brenol; Geraldo da Rocha Castelar Pinheiro
Journal:  Adv Rheumatol       Date:  2021-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.